Dyne Therapeutics Q3 EPS $(0.83) Up From $(2.01) YoY
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.83) per share. This is a 58.71 percent increase over losses of $(2.01) per share from the same period last year.
Dyne Therapeutics Highlights Preclinical Data And Clinical Development Plans For DMD And DM1 Programs at Inaugural R&D Day
Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 -
- Event also Features
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
Dyne Therapeutics Inc (NASDAQ:DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its…
Dyne Therapeutics To Present At Chardan’s Virtual 5th Annual Genetic Medicines Conference
Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is
Dyne Therapeutics Presents New In Vivo Data For Its Myotonic Dystrophy Type 1 Candidate Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new in vivo data
Dyne Therapeutics Q2 EPS $(0.58) Up From $(3.31) YoY
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.58) per share. This is a 82.48 percent increase over losses of $(3.31) per share from the same period last year.
Dyne Therapetuics Highlights Presentation Of Preclinical Data From Facioscapulohumeral Musclar Dystrophy Program During FSHD Society Int’l. Research Congress
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line -
WALTHAM, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Dyne
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune’s Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)
Dyne Therapeutics’ Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained…